- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Use of PARP Inhibitors in Ovarian Cancer
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
Video content is prompted by the following:
PARP Inhibitors in Ovarian Cancer Treatment
Key Themes:
- Biomarker-directed PARP inhibitor use in frontline treatment
- Current FDA approvals and indications
- Overall survival concerns in platinum-sensitive settings
Notable Insights:
- Current frontline approvals:
- Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum
- Olaparib with bevacizumab for HRD-positive tumors
- Niraparib approved for all-comers whose tumors responded to chemotherapy
- Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
- The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.
Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use them is in frontline...there is the chance we are curing more patients. We believe that.”
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD
May 21st 2025The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
Read More
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More
